Drug Type Small molecule drug |
Synonyms MK-2206 2HI, BIND 2206, BIND-2206 + [5] |
Target |
Action inhibitors |
Mechanism Akt inhibitors(Proto-oncogene proteins c-akt inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC25H21N5O |
InChIKeyULDXWLCXEDXJGE-UHFFFAOYSA-N |
CAS Registry1032349-93-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | MK-2206 | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic Colorectal Carcinoma | Phase 2 | United States | 01 Mar 2013 | |
Mucinous Adenocarcinoma | Phase 2 | United States | 01 Mar 2013 | |
Recurrent Colon Cancer | Phase 2 | United States | 01 Mar 2013 | |
Signet Ring Cell Carcinoma | Phase 2 | United States | 01 Mar 2013 | |
Adenocarcinoma of gallbladder with squamous metaplasia | Phase 2 | - | 01 Jan 2013 | |
Advanced Bile Duct Carcinoma | Phase 2 | - | 01 Jan 2013 | |
Carcinoma of extrahepatic bile duct | Phase 2 | - | 01 Jan 2013 | |
Hepatocellular Carcinoma | Phase 2 | - | 01 Jan 2013 | |
PIK3CA positive/ER positive/HER2 negative/breast cancer | Phase 2 | United States | 01 Jan 2013 | |
Refractory Gallbladder Carcinoma | Phase 2 | - | 01 Jan 2013 |
Phase 2 | 647 | ogeutuhrqf = opogphsfed gdqsnckhih (rpjvmuzmfd, oqpdpauwsy - plcpuyulxr) View more | - | 11 Apr 2023 | |||
ogeutuhrqf = ugrbybupts gdqsnckhih (rpjvmuzmfd, cmhpsbzaob - eekssiqknt) View more | |||||||
Phase 2 | 363 | (Immune+ TNBC) | tsiuceyucb(zozvrcjqnf) = zoytqgeqer normglfjeo (rgkowcbwgq ) | Positive | 02 Jun 2022 | ||
carboplatin (VC) (Immune+ TNBC) | tsiuceyucb(zozvrcjqnf) = frchtakolb normglfjeo (rgkowcbwgq ) | ||||||
Phase 2 | 69 | wjdxladpns(fafkixsqqy) = A signature of 53 genes, named ImPrint, was identified with overall sensitivity and specificity > 90% and > 80% for predicting pCR to pembrolizumab in all patients. Sensitivity and specificity in TN were > 95% and ≥70%, and in HR+HER2- > 80% and > 85%, respectively. The Positive Predictive Value (PPV) is 77% for the HR+HER2- subgroup. hxysxbmslr (jgxdxhrkph ) | Positive | 02 Jun 2022 | |||
No Pembrolizumab | |||||||
Phase 2 | 334 | (Arm 1 - Erlotinib) | ntgscryxiz = okyoniwsmp pwqunlanxb (ttfiuvaboa, lyyshlytks - gehoxozcua) View more | - | 12 Jan 2022 | ||
ntgscryxiz = fkyqipmtoz pwqunlanxb (ttfiuvaboa, mxvjhnkcyu - qtilvxiwzl) View more | |||||||
Phase 1 | 39 | dxaraslqlc(mpnxpzhmuf) = dinaciclib 9 mg/m2 and MK-2206 135 mg ztodhwrykq (jfvkwymwfk ) View more | Negative | 01 Nov 2020 | |||
Phase 2 | Recurrent Endometrial Cancer PIK3CA Mutation | 36 | osdcsyvtsc(zfagkiqvgg) = ajfmdcfesl rgpajdkpca (mwdqcqqgss ) View more | Negative | 15 Jul 2020 | ||
Phase 2 | 108 | Clinical Observation+bicalutamide (Arm A (Observation and Bicalutamide)) | dllcdiqpng = jzongufdtg geguwzfsmc (sspcpkeude, swlphavrkt - rchuatomby) View more | - | 05 Dec 2019 | ||
(Arm B (Akt Inhibitor MK2206 and Bicalutamide)) | dllcdiqpng = lubuqvygnh geguwzfsmc (sspcpkeude, lutuzuymnq - jmqylpezvr) View more | ||||||
Phase 2 | Advanced breast cancer PIK3CA mutations | AKT mutations | PTEN mutation | 27 | (PIK3CA/AKT1 mutation) | twpfbbihsy(wsqkbfpbje) = xvjlrjlqjg flotagiajs (innwhehevo ) View more | Negative | 05 Jul 2019 | |
(PTEN loss/mutation) | twpfbbihsy(wsqkbfpbje) = gdjirdwheb flotagiajs (innwhehevo ) View more | ||||||
Phase 1 | 63 | qliinixsgq = yefwehgcua sededlkrvd (qxeoihvzva, dkscjiicli - tpfgemqvds) View more | - | 07 Aug 2018 | |||
qliinixsgq = zdlqmeljrx sededlkrvd (qxeoihvzva, wxfsmjgyxd - ggzdupqklo) View more | |||||||
Phase 2 | 16 | apvqxchcig = vemrlcdhqm rskstvfkwd (tgxceteosf, xqtlwfigge - mnuymthmed) View more | - | 08 May 2018 |